Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Atherosclerosis

• Publication date

  1996-01-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0021-9150(95)05649-1PMID 8808497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low‐density‐lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment

  1995cited by this paper
• Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.

  1995cited by this paper
• Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.

  1995cited by this paper
• Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

  1995cited by this paper
• Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects.

  1995cited by this paper
• Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

  1995cited by this paper
• Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.

  1994cited by this paper
• Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.

  1994cited by this paper
• Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.

  1994cited by this paper
• Simultaneous determination of mevalonate and 7 alpha-hydroxycholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis.

  1993cited by this paper
• Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations.

  1993cited by this paper
• Genetic Determinants of Responsiveness to the HMG‐CoA Reductase Inhibitor Fluvastatin in Patients With Molecularly Defined Heterozygous Familial Hypercholesterolemia

  1993cited by this paper
• Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.

  1993cited by this paper
• The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism.

  1993cited by this paper
• How effective is drug therapy in heterozygous familial hypercholesterolemia?

  1993cited by this paper
• The discovery and development of HMG-CoA reductase inhibitors.

  1992cited by this paper
• Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.

  1992cited by this paper
• Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.

  1992cited by this paper
• Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis

  1992cited by this paper
• Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.

  1991cited by this paper
• Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry.

  1991cited by this paper
• Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.

  1991cited by this paper
• Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases.

  1990cited by this paper
• Regulation of the mevalonate pathway

  1990cited by this paper
• The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia

  1990cited by this paper
• Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

  1990cited by this paper
• Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.

  1990cited by this paper
• The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.

  1990cited by this paper
• Cholesterol is required for secretion of very-low-density lipoprotein by rat liver.

  1989cited by this paper
• Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.

  1989cited by this paper
• Serum noncholesterol sterols related to cholesterol metabolism in familial hypercholesterolemia.

  1988cited by this paper
• Multiple crm- mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions.

  1988cited by this paper
• Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

  1987cited by this paper
• Transcriptional regulation of the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene in rat liver.

  1985cited by this paper
• Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

  1984cited by this paper
• Plasma mevalonate as a measure of cholesterol synthesis in man.

  1984cited by this paper
• Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man.

  1982cited by this paper
• A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

  1978cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease

  2024cites this paper
• Familial hypercholesterolaemia.

  2024cites this paper
• 2024 Egyptian consensus statement on the role of non-statin therapies for LDL cholesterol lowering in different patient risk categories

  2024cites this paper
• Synthesis, Characterization and In vitro Evaluation of N-Substituted- Sulfomoyl-Phenyl-Amino Carboxylic Acid Derivatives as Squalene Synthase Inhibitors

  2019cites this paper
• Statins redux: A re-assessment of how statins lower plasma cholesterol

  2017cites this paper
• Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia

  2016cites this paper
• Efecto del tamoxifeno, raloxifeno y toremifeno sobre la actividad y expresión del receptor de LDL en linfocitos primarios humanos

  2016cites this paper
• Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice

  2016cites this paper
• Étude du polymorphisme rs3846662 de l’HMGCR dans le cerveau et le système périphérique

  2016cites this paper
• Lipid-lowering efficacy of atorvastatin.

  2015cites this paper
• Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes

  2015cites this paper
• Physiological feedback regulation of cholesterol biosynthesis: Role of translational control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols.

  2015cites this paper
• Effect of mevalonic acid on cholesterol synthesis in bovine intramuscular and subcutaneous adipocytes

  2015cites this paper
• Respuesta a las estatinas en prevención cardiovascular: evaluación de los hiporrespondedores

  2014cites this paper
• Quantification of urinary mevalonic acid as a biomarker of HMG-CoA reductase activity by a novel translational LC-MS/MS method.

  2014cites this paper
• Lipoprotein apheresis: state of the art and novelties.

  2013cites this paper
• Response to Statins in Cardiovascular Prevention: Hypo-Responders´ Evaluation

  2013cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Medical Lipid-Regulating Therapy

  2012cites this paper
• Atorvastatin

  2012cites this paper
• Squalene monooxygenase – a target for hypercholesterolemic therapy

  2011cites this paper
• Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

  2011cites this paper
• Effect of Atorvastatin on Lipid Profile and Mevalonic Acid Levels , a Biomarker in North Indian Normocholesterolemic Subjects

  2011cites this paper
• Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial[S]

  2010cites this paper
• Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia.

  2010cites this paper
• Two novel D151Y and M391T LDLR mutations causing LDLR transport defects in Thai patients with familial hypercholesterolemia.

  2010cites this paper
• Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia

  2010cites this paper
• patient-oriented and epidemiological research Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

  2009cites this paper
• Antiplatelet ‘resistance’ and ‘non‐responders’: what do these terms really mean?

  2009cites this paper
• Simvastatin as a potential therapeutic for acute respiratory distress syndrome.

  2009cites this paper
• Determination of Key Intermediates in Cholesterol and Bile Acid Biosynthesis by Stable Isotope Dilution Mass Spectrometry

  2008cites this paper
• Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.

  2007cites this paper
• Strategies in prevention and prevention of heparine induced trombocytopenia

  2007cites this paper
• Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment.

  2007cites this paper
• Effects of phytosterols in diacylglycerol as part of diet therapy on hyperlipidemia in children.

  2007cites this paper
• Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy.

  2006cites this paper
• Validation of the LC-MS/MS method for the quantification of mevalonic acid in human plasma and determination of the matrix effect Published, JLR Papers in Press, July 21, 2006.

  2006cites this paper
• Molecular mechanisms of cholesterol absorption and transport in the intestine.

  2005cites this paper
• Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

  2004cites this paper
• Increased Sensitivity to Dietary Cholesterol in Diabetic and Hypothyroid Rats Associated with Low Levels of Hepatic HMG-CoA Reductase Expression

  2004cites this paper
• Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.

  2004cites this paper
• Hepatic HMG-CoA Reductase Expression and Resistance to Dietary Cholesterol

  2004cites this paper
• The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk

  2003cites this paper
• A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.

  2003cites this paper
• Excursions in biomedical mass spectrometry.

  2003cites this paper
• Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

  2003cites this paper
• Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard.

  2003cites this paper
• Squalene Synthase Inhibitors

  2003cites this paper
• Why some patients respond poorly to statins and how this might be remedied.

  2002cites this paper
• Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.

  2002cites this paper
• Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.

  2002cites this paper
• Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors

  2002cites this paper
• Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients.

  2002cites this paper
• Efficacy and therapeutic potential of plant sterols.

  2002cites this paper
• Effects of pravastatin sodium on mevalonate metabolism in common marmosets.

  2002cites this paper
• A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism.

  2002cites this paper
• Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia

  2001cites this paper
• AtorvastatinReview of its Pharmacological Properties and Use in Dyslipidaemia

  2001cites this paper
• Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

  2001cites this paper
• Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread.

  2001cites this paper
• Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity.

  2000cites this paper
• Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.

  2000cites this paper
• Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.

  2000cites this paper
• Flow Cytometric Assessment of Effects of Fluvastatin on Low‐Density Lipoprotein Receptor Activity in Stimulated T‐Lymphocytes from Patients with Heterozygous Familial Hypercholesterolemia

  2000cites this paper
• Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.

  2000cites this paper
• Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase: The Concept of Cholesterol Buffering Capacity (44508)

  2000cites this paper
• Statins: effective antiatherosclerotic therapy.

  2000cites this paper
• The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs1.

  1999cites this paper
• The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.

  1999cites this paper
• Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.

  1999cites this paper
• Manipulation of cholesterol and cholesteryl ester synthesis has multiple effects on the metabolism of apolipoprotein B and the secretion of very-low-density lipoprotein by primary hepatocyte cultures.

  1999cites this paper
• Effect of inhibiting HMG‐CoA reductase on 7α‐hydroxy‐4‐cholesten‐3‐one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up‐regulation of the latter pathway

  1999cites this paper
• Metabolic modes of action of the statins in the hyperlipoproteinemias.

  1998cites this paper
• Dietary cholesterol regulates hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in rats primarily at the level of translation.

  1998cites this paper
• Enzyme immunoassay of urinary mevalonic acid and its clinical application.

  1998cites this paper
• HMG-CoA reductase is not the site of the primary defect in phytosterolemia.

  1998cites this paper
• Management of Dyslipidaemias

  1998cites this paper
• Management of Dyslipidaemias The Potential Role of Atorvastatin

  1998cites this paper
• ANALYSIS OF LEUKOTRIENES AND LIPOXINS

  1998cites this paper
• Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.

  1998cites this paper
• Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression.

  1998cites this paper
• Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.

  1998cites this paper
• An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.

  1998cites this paper
• Use of cholesterol precursors to assess changes in cholesterol synthesis under non‐steady‐state conditions

  1998cites this paper
• Cholesterol synthesis is increased in mixed hyperlipidaemia.

  1998cites this paper
• Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias

  1998cites this paper
• The Mevalonate Pathway and Renal Diseases: Experimental and Clinical Implications

  1998cites this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion.

  1997cites this paper
• Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.

  1997cites this paper
• Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolemia. The Familial Hypercholesterolaemia Regression Study Group.

  1997cites this paper
• A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.

  1997cites this paper
• Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.

  1997cites this paper
• Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors

  1997cites this paper
• Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolaemic subjects: evidence for a threshold effect.

  1997cites this paper
• Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.

  1997cites this paper
• The Role of Hmg-CoA Reductase Inhibitors in Homozygous Familial Hypercholesterolemia

  1996cites this paper
• Role of cholesterol in regulating apolipoprotein B secretion by the liver.

  1996cites this paper